Related references
Note: Only part of the references are listed.Bevacizumab for Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen: Clinical and Economic Impact
Gary Shienbaum et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2012)
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
Nicholas Papadopoulos et al.
ANGIOGENESIS (2012)
Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration
Matthew Ohr et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Combined Intravitreal Bevacizumab and Trabeculectomy With Mitomycin C Versus Trabeculectomy With Mitomycin C Alone for Neovascular Glaucoma
Yuji Takihara et al.
JOURNAL OF GLAUCOMA (2011)
Mini Drug Pump for Ophthalmic Use
Saloomeh Saati et al.
CURRENT EYE RESEARCH (2010)
A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration Clinical and Economic Impact
Omesh P. Gupta et al.
OPHTHALMOLOGY (2010)
Intravitreal Bevacizumab for Neovascular Glaucoma A Randomized Controlled Trial
Shahin Yazdani et al.
JOURNAL OF GLAUCOMA (2009)
Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases
Taku Wakabayashi et al.
OPHTHALMOLOGY (2008)
Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy
Donald S. Fong et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2007)
Intravitreal bevacizumab (Avastin®) in the treatment of neovascular glaucoma
Milko E. Iliev et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2006)
Regression of neovascular iris vessels by intravitreal injection of bevacizumab
John O. Mason et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2006)
Intracameral bevacizumab for iris rubeosis
Salvatore Grisanti et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2006)
Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular enclothelial growth factor therapy in multiple models of ocular neovascularization
Nobuo Jo et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
G Bergers et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic) acid microspheres
KG Carrasquillo et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2003)
VEGF-Trap: A VEGF blocker with potent antitumor effects
J Holash et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
P Carmeliet et al.
NATURE MEDICINE (2001)
Share Paper
